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MUTANTS OF COCAINE ESTERASE 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
2 
linked to the mutant CocE polypeptide. In some embodi-
ments, the composition further includes a plurality of poly-
meric molecules coating the mutant CocE polypeptide. 
Another aspect provides a nucleic acid molecule encoding 
5 the mutant CocE polypeptide. 
Another aspect provides a method of treating a cocaine-
induced condition via administering an effective amount of 
a composition as described above and herein to a subject in 
need thereof. 
The present application claims the benefit of priority to 
PCT International Application No. PCT/US14/49990 filed 6 
Aug. 2014, which claims the benefit of U.S. Provisional 
Application Ser. No. 61/862,955 filed 6 Aug. 2013; each of 
which is incorporated herein by reference in its entirety. 10 Other objects and features will be in part apparent and in 
part pointed out hereinafter. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
Not Applicable. 
MATERIAL INCORPORATED-BY-REFERENCE 
The Sequence Listing, which is a part of the present 
disclosure, includes a computer readable form comprising 
nucleotide and/or amino acid sequences of the present 
invention. The subject matter of the Sequence Listing is 
incorporated herein by reference in its entirety. 
BACKGROUND OF THE INVENTION 
Cocaine is a highly addictive substance of abuse and its 
use maintains the drug-taking habit by directly affecting the 
reward pathways. Cocaine use can have detrimental physical 
and emotional consequences. Regardless of the frequency of 
use cocaine users can experience heart attacks or strokes. 
Cocaine abusers can also subject to experiencing anxiety, 
depression, or paranoia. Currently there are no small mol-
ecule drugs that can block the addictive or toxic effects of 
cocaine. However, it has been shown that an enzyme called 
cocaine esterase (CocE) can accelerate the breakdown of 
circulating cocaine or reduce its effects. Bacterial CocE has 
been found to be easily expressed or purified (Kca,=7.8 s- 1 
15 
DESCRIPTION OF THE DRAWINGS 
Those of skill in the art will understand that the drawings, 
described below, are for illustrative purposes only. The 
drawings are not intended to limit the scope of the present 
teachings in any way. 
FIG. 1 is a PYMOL-generated 3D configuration of CocE 
20 polypeptide with locations of cysteine mutations labeled. 
FIG. 2 is a structural model of CocE with Cys 551, Asp 
18, Lys 315, and Thr 436 positions labeled. 
FIG. 3 is a series of line and scatter plots and data 
depicting the functional kinetic changes resulting from a 
25 structural change from substitution of cysteine in CocE. 
FIG. 3A is a line and scatter plot of the Lys2: Cl 07S, C429S 
CocE mutation and corresponding Activity data. FIG. 38 is 
a line and scatter plot oftheAla328: C107S, C429S, A328C 
CocE mutation and corresponding activity data. FIG. 3C is 
30 a line and scatter plot of the Thr12: C107S, C429S, T436C 
CocE mutation and corresponding activity data. FIG. 3D is 
a line and scatter plot of the Val434: C107S, C429S, V434C 
CocE mutation and corresponding activity data. 
FIG. 4 is a drawing depicting the removal ofCys 107 and 
35 Cys 429. 
Km =<1 µM). Administration of a cocaine esterase (CocE) 
can decrease the half-life of cocaine in both the brain or 40 
FIG. 5 is a drawing depicting the removal ofCys 107 and 
replacing with Ala and leaving Cys 429 as is in one CocE 
and removal of Cys429 and replacing with Ala and leaving 
the Cys 107 as is. 
FIG. 6 is a cartoon depicting strategy for study of addi-
tional mutations. plasma. A major hurdle with using CocE as a therapeutic is 
that it can be unstable and can be quickly degraded. 
A strategy to antagonize the negative effects of cocaine 
has been to increase its metabolism by using cocaine-
specific enzymes, such as cocaine esterase (CocE). The use 45 
of cocaine specific enzymes have shown to decrease the 
half-life of cocaine in both the plasma and in the brain. But 
a limitation is that CocE can be unstable in vivo and can 
have a very low half-life. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present disclosure is based, at least in part, on the 
discovery that mutations made to CocE can increase stability 
or enzymatic efficiency. As shown herein, mutations of 
CocE and optional linkage to a polymeric molecule can 
SUMMARY OF THE INVENTION 
50 enhance the pharmaceutical properties of cocaine esterase 
(CocE) by shielding of antigenic or immunogenic epitopes, 
preventing degradation by proteolytic enzymes, increasing 
water-solubility, reducing the renal filtration, or altering 
biodistribution. Approaches identified can include linkage of 
Among the various aspects of the present disclosure is the 
provision of a composition including an isolated mutant 
cocaine esterase (CocE) polypeptide. In some embodiments, 
the CocE polypeptide of the composition has an amino acid 
sequence having at least about 95% sequence identity to 
SEQ ID NO: 1 and one or more substitution, addition or 
deletion selected from the group consisting of C107S, 
C429S, C551S, A328C, DISC, T436C, V434C, L163V; 60 
V121D; S167A, W52L, Q123E, S159A, T122A, S140A, 
T172R, G173Q, S265A, W220A, A193D, and Y532F, 
wherein the polypeptide has cocaine esterase activity. 
In some embodiments, the composition further includes a 
polymeric molecule chemically linked to the mutant CocE 
polypeptide. In some embodiments, the composition further 
includes a plurality of polymeric molecules chemically 
55 a CocE and a polymeric molecule, such as site-directed 
coating of the protein, e.g., through PEGylation. Attaching 
a hydrophilic polymer can make the proteins less immuno-
genic (e.g., as shown in asparaginase and adenosine-deami-
nase) and provide other benefits described more fully below. 
A sulfhydryl group of a cysteine amino acid residue on the 
surface of a protein can be an ideal site for attachment of a 
polymeric molecule. Site directed mutagenesis can allow 
substitution of a cysteine for any amino acid in the primary 
sequence of CoCE. The placement of a plurality of cysteines 
65 for use as attachment sites for large polymeric molecules can 
require that they be distributed over the surface of CoCE. If 
not distributed, then reaction at one cysteine may block 
US 10,160,960 B2 
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reaction at an adjacent cysteine. Because an initial reaction 
can occur randomly at two sites, the result can be a mixture. 
If there are several cysteines that are poorly distributed, the 
result can be a complex mixture. Such mixtures may be 
undesirable because the activity and stability of a mutant 
CoCE may not be attributed to a single chemical entity and 
thus may not be optimized effectively. Not only can cyste-
ines introduced into CoCE react but native cysteines can 
also couple with activated polymeric molecules and if not 
effectively distributed, the result can be an undesirable 
complex mixture. But native cysteines can contribute to the 
stability and efficiency of enzymes, and their removal may 
not be tolerated in some embodiments. In some embodi-
ments, determination of whether a particular amino acid can 
be substituted for a native cysteine is determined through 
experimentation. 
4 
SEQ ID NO: 1). A cysteine residue of a CocE polypeptide 
can be replaced by one or more amino acids such that CocE 
activity is retained or stability is increased. For example, one 
of more cysteine resides of CocE can be replaced with a 
serine residue (e.g., C107S, C429S, C551 S, or C477S from 
SEQ ID NO: 1 ). The above listed mutations can be in 
combination with ( e.g., in addition to) other mutations 
described herein. 
In some embodiments, one or more native cysteine resi-
10 dues of CoCe can be substituted so as to remove ineffective 
distribution of cysteines that can result in undesirable com-
plex mixture. In various embodiments, an additional one or 
more cysteines can be introduced so as to provide an 
optimized distribution (e.g., a geometrically optimized dis-
15 tribution) of cysteines to form an effective anchor point for 
attachment of one or more polymer molecules to CocE. For 
example, C107 and C429 can be removed and an additional 
one or more cysteines can be substituted (e.g., K315C; 
As shown herein, various mutations were made and 
identified in CocE that remove poorly distributed native 
cysteines without unacceptable loss of stability and enzy-
matic efficiency. Mutant variants of CocE and coated CocE 20 
mutants disclosed herein can be designed to have an amino 
acid structure unencumbered by poorly distributed surface 
cysteines. Accordingly, various CocE mutants can be used 
for developing mutants with added cysteines so as to 
develop coated CoCE mutants for use as an effective enzyme 
therapy for cocaine intoxication and addiction in humans. 
T436C; N19Cs; V434C; or A328C). 
A mutant CocE polypeptide can have an amino acid 
sequence according to SEQ ID NO: 1, or a variant thereof 
having at least about 80% sequence identity ( e.g., at least 
about 85%, at least about 90%, at least about 95%, at least 
about 96%, at least about 97%, at least about 98%, or at least 
25 about 99% ), with one or more mutations described herein 
and retaining cocaine esterase activity. For example, a 
mutant CocE polypeptide can have an amino acid sequence 
according to SEQ ID NO: 1, or a variant thereof having at 
least about 80% sequence identity ( e.g., at least about 85%, 
In various embodiments, one or more specific mutations 
of cysteine (C) ( e.g., to serine (S)) can be made to CocE. As 
stated, poorly distributed native cysteine residues can be a 
major contributing factor for complex mixtures of polymeric 
coated CocE. Exemplary mutations include: C107; C429; 
C551; or C477. While in no way limiting the present 
disclosure, it is presently thought that C107, C429, or C551 
are exposed to solvent and could be maldistributed relative 
to the ideal substitution of surface cysteines for attachment 
of polymeric molecules. While in no way limiting the 
present disclosure, it is presently thought that C477 may be 
a conserved structural component. Activity assays of other 
CocE constructs which contain mutations including C107S 
or C429S mutations determined the Michaelis constant 
(Km) and maximal reaction velocity (Vmax) of the mutants 
compared to wild-type control. 
CocE mutants, as described herein, can be used to protect 
against the toxic effect of cocaine, treat and prevent cocaine 
addiction, reduce the plasma levels of cocaine in an over-
dose emergency, or improve the efficacy of long-lasting 
cocaine esterase as a biologic therapeutic. 
MUTANT CocE POLYPEPTIDES 
Described herein are CocE mutant polypeptides. A mutant 
CocE polypeptide can have an amino acid sequence of a 
CocE polypeptide ( e.g., a wild-type CocE) with one or more 
mutations (e.g., substitution, addition, or deletion). For 
example, a mutant CocE polypeptide can have an amino acid 
sequence of wild type CocE fromRhodococcus sp. (SEQ ID 
NO: 1) with at least one or more mutations (e.g., substitu-
tion, addition, or deletion). As another example, a mutant 
CocE polypeptide can have at least about 80% sequence 
identity to SEQ ID NO: 1 ( e.g., at least about 85%, at least 
about 90%, at least about 95%, at least about 96%, at least 
about 97%, at least about 98%, or at least about 99%) and 
having at least one or more mutations described herein and 
substantially retaining CocE activity or increased stability. 
In some embodiments, a mutation of a CocE polypeptide 
can provide for increased stability by removing or replacing 
an amino acid residue associated with instability. For 
example, a mutation of a CocE can replace or eliminate a 
cysteine residue (e.g., C107, C429, C551, or C477 from 
30 at least about 90%, at least about 95%, at least about 96%, 
at least about 97%, at least about 98%, or at least about 
99%), with one or more mutations at positions C107, C429, 
C551, or C477 (e.g., C107S, C429S, C551S, or C477S). In 
some embodiments, mutations at positions C107, C429, 
35 C551, or C477 are not C107A, C429A, C551A, or C477A, 
respectively (see e.g., Example 5, Table 1). 
A mutant CocE polypeptide can have an amino acid 
sequence according to SEQ ID NO: 1, or a variant thereof 
having at least about 80% sequence identity ( e.g., at least 
40 about 85%, at least about 90%, at least about 95%, at least 
about 96%, at least about 97%, at least about 98%, or at least 
about 99%), with one or more mutations of A328C, DISC, 
T436C, V434C, L163V; V121D; S167A, W52L, Q123E, 
S159A, T122A, S140A, T172R, S265A, W220A,A193D, or 
45 Y532F (including but not limited to combinations with 
mutations at positions C107, C429, C551, or C477). A 
mutant CocE polypeptide can have an amino acid sequence 
according to SEQ ID NO: 1, or a variant thereof having at 
least about 80% sequence identity ( e.g., at least about 85%, 
50 at least about 90%, at least about 95%, at least about 96%, 
at least about 97%, at least about 98%, or at least about 
99%), with one or more mutations ofC107S, C429S, C551 
S, C477S, A328C, DISC, T436C, V434C, L163V; V121D; 
S167A, W52L, Q123E, S159A, T122A, S140A, T172R, 
55 S265A, W220A, A193D, or Y532F. The above listed muta-
tions can be in combination with ( e.g., in addition to) other 
mutations described herein. 
A mutant CocE polypeptide can have an amino acid 
sequence according to SEQ ID NO: 1, or a variant thereof 
60 having at least about 80% sequence identity ( e.g., at least 
about 85%, at least about 90%, at least about 95%, at least 
about 96%, at least about 97%, at least about 98%, or at least 
about 99%), with one or more mutations of: C107S and 
C429S; C107S, C429S, and A328C; DISC, C107S, and 
65 C429S; C107S, C429S, T436C; or C107S, C429S, and 
V 434C. The above listed mutations can be in combination 
with ( e.g., in addition to) other mutations described herein. 
US 10,160,960 B2 
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A mutant CocE polypeptide can have an amino acid CocE mutations, which are suitable for uses and methods 
sequence according to SEQ ID NO: 1, or a variant thereof according to the present invention are disclosed in US Pat 
having at least about 80% sequence identity (e.g., at least Pub No. 2013/0039900, published 14 Feb. 2013. 
about 85%, at least about 90%, at least about 95%, at least Polymer 
about 96%, at least about 97%, at least about 98%, or at least 5 A mutant CocE polypeptide can be linked to a polymeric 
about 99%), with one or more mutations of R41I, N42V, molecule. A polymer molecule for linking to a CocE poly-
y 44F, D45R, F47R, K46A, S56G, T74S, F84Y, Sll 7 A, peptide can be non-toxic, non-immunogenic, non-antigenic, 
L119A, Gl 73Q, S140A, L146P, A149S, Y152H, S159A, highly soluble in water, or FDA approved. A mutant CocE 
V160A, L163V, L169K, G171A, T172R, G173A, G173Q, polypeptide can comprise a polymeric coating. 
L174R, S177Q, A181K, S179R, R182K, F189A, F189K, 10 A polymeric molecule for linkage or coating a mutant 
F189L, V190K, Q191K, A193D, A194K, A194R, N197K, CocE polypeptide can have a molecular weight suitable to 
I218L, W220A, V225I, T254R, V262L, S265A, W285T, achieve benefits described herein without sacrificing CocE 
A310D, C477T, L508G, K531A, Y532F, D533S, T172R/ activity or incurring other negative effects. For example, a 
G173Q, T172R/A193D, T172R/F189K, T172R/G173Q- polymeric molecule for linkage or coating a mutant CocE 
I175-G-G-A186, G171Q/T172R/G173Q, T172R/G173Q- 15 polypeptide can have a molecular weight of about 300 
Tl 76-G-G-D185, Gl 73Q-Il 75-G-G-A186, Gl 73Q-T176- Daltons up to about 20,000 Daltons. As another example, a 
G-G-D185, I175-G-G-A186, Tl 76-G-G-D185, wt-Il 75-G- polymeric molecule for linkage or coating a mutant CocE 
D185, wt-T176-G-G-D185, and F189A/T172R. In some polypeptide can have a molecular weight of about 500 
embodiments, a mutant CocE polypeptide has at least a Daltons, about 7 50 Dal tons, about 1000 Daltons, about 1500 
G 173Q mutation. The above listed mutations can be in 20 Daltons, about 2000 Daltons, about 2500 Dal tons, about 
combination with ( e.g., in addition to) other mutations 3000 Daltons, about 3500 Dal tons, about 4000 Daltons, 
described herein. about 4500 Daltons, about 5000 Daltons, about 5500 Dal-
A mutant CocE polypeptide can have an amino acid tons, about 6000 Daltons, about 6500 Daltons, about 7000 
sequence according to SEQ ID NO: 1, or a variant thereof Daltons, about 7500 Daltons, about 8000 Daltons, about 
having at least about 80% sequence identity (e.g., at least 25 8500 Daltons, about 9000 Daltons, about 9500 Daltons, 
about 85%, at least about 90%, at least about 95%, at least about 10000 Daltons, about 10500 Daltons, about 11000 
about 96%, at least about 97%, at least about 98%, or at least Daltons, about 11500 Daltons, about 12000 Daltons, about 
about 99%), with one or more mutations of R75K, F78C, 12500 Daltons, about 13000 Daltons, about 13500 Daltons, 
F78R, A79K, A79R, Y118S, V121Y, L164K, W166R, about 14000 Daltons, about 14500 Daltons, about 15000 
I170V, G173Q, T176R, S177C, K315C, G171S, D180K, 30 Daltons, about 15500 Daltons, about 16000 Daltons, about 
P183K, F78C/Sl 77C, or Y118S/V121 Y. In some embodi- 16500 Daltons, about 17000 Daltons, about 175000 Daltons, 
ments, a mutant CocE polypeptide has at least a G 173Q about 18000 Daltons, about 18500 Daltons, about 19000 
mutation. The above listed mutations can be in combination Daltons, about 19500 Daltons, or about 20000 Daltons. It is 
with (e.g., in addition to) other mutations described herein. understood that the ranges between each of the above listed 
A mutant CocE polypeptide can have an amino acid 35 molecular weights are included in the present disclosure. It 
sequence according to SEQ ID NO: 1, or a variant thereof is understood that the above described molecular weights 
having at least about 80% sequence identity ( e.g., at least and ranges thereof apply generically to polymeric molecules 
about 85%, at least about 90%, at least about 95%, at least and specifically to polymeric molecules such as polyethyl-
about 96%, at least about 97%, at least about 98%, or at least ene glycol, described more fully below. 
about 99%), with one or more mutations ofC107S, C429S, 40 In some embodiments, a polymeric molecule for linking 
C551S, C477S, A328C, DISC, T436C, V434C, L163V, to a mutant CocE polypeptide comprises: 2-[2-(Boc-amino) 
V121D, S167A, W52L, Q123E, S159A, T122A, S140A, ethoxy]ethoxyacetic acid (dicyclohexylammonium); 21-
T172R, S265A, W220A, A193D, Y532F, R41I, N42V, (Boc-amino)-4,7,10,13,16,19-hexaoxaheneicosanoic acid 
Y44F, D45R, F47R, K46A, S56G, T74S, F84Y, S117A, purum; 15-(Boc-amino)-4,7,10,13-tetraoxapentadecanoic 
L119A, G173Q, S140A, L146P, A149S, Y152H, S159A, 45 acid puruni; N-Boc-2,2'-(ethylenedioxy)diethylamine; 
V160A, L163V, L169K, G171A, T172R, G173A, G173Q, N-Boc-N'-succinyl-4,7,10-trioxa-l,13-tridecanediamine; 
L174R, S177Q, A181K, S179R, R182K, F189A, F189K, 2-[2-(Fmoc-amino)ethoxy]ethanol; N-Fmoc-N"-succinyl-4, 
F189L, V190K, Q191K, A193D, A194K, A194R, N197K, 7,10-trioxa-1,13-tridecanediamine; 4,7,10,13,16,19,22,25, 
I218L, W220A, V225I, T254R, V262L, S265A, W285T, 32,35,38,41,44,47,50,53-Hexadecaoxa-28,29-dithiahexa-
A310D, C477T, L508G, K531A, Y532F, D533S, T172R/ 50 pentacontanedioic acid; 4,7,10,13,16,19,22,25,32,35,38,41, 
G 173Q, Tl 72R/ A193D, Tl 72R/Fl 89K, Tl 72R/G 173Q- 44,47,50,53-Hexadecaoxa-28,29-
Il 75-G-G-Al 86, G 171 Q/Tl 72R/G 173Q, Tl 72R/G 173Q- dithiahexapentacontanedioic acid di-N-succinimidyl ester; 
Tl 76-G-G-D185, Gl 73Q-Il 75-G-G-A186, Gl 73Q-Tl 76- 0,0'-Bis(2-aminoethyl)octadecaethylene glycol; {2-[2-
G-G-Dl85, I175-G-G-A186, Tl 76-G-G-Dl85, wt-Il 75-G- (Fmoc-amino )ethoxy]ethoxy}acetic acid; 2-[2-(2-Methoxy-
D185, wt-T176-G-G-D185, F189A/T172R, R75K, F78C, 55 ethoxy)ethoxy]acetic acid; methoxypolyethylene glycol 
F78R, A79K, A79R, Y118S, V121Y, L164K, W166R, maleimide; 0-(2-Azidoethyl)-0'-methyl-triethylene glycol; 
I170V, G173Q, T176R, S177C, K315C, G171S, D180K, 0-(2-Azidoethyl)-0'-methyl-undecaethylene glycol; 0-(2-
P183K, F78C/S177C, or Y118S/V121Y. In some embodi- Azidoethyl)nonadecaethylene glycol; 0,0'-Bis[2-(N-Suc-
ments, a mutant CocE polypeptide has at least a G 173Q cinimidyl-succinylamino )ethyl]polyethylene glycol; 0,0'-
mutation. The above listed mutations can be in combination 60 Bis[2-(N-Succinimidyl-succinylamino )ethyl]polyethylene 
with ( e.g., in addition to) other mutations described herein. glycol; 0-(3-Carboxypropyl)-0'-[2-(3-mercaptopropio-
CocE mutations, which are suitable for uses and methods nylamino)ethyl]-polyethylene glycol; O-[N-(3-Maleimi-
according to the present invention are disclosed in U.S. Pat. dopropionyl)aminoethyl]-0'-[3-(N-succinimidyloxy)-3-
No. 8,318,156, issued 27 Nov. 2012, which is incorporated oxopropyl]triethylene glycol; Methoxypolyethylene glycol 
herein in its entirety with regard to the generation of mutant 65 azide PEG; Methoxypolyethylene glycol maleimide; or 
CocE polypeptides, transformation, purification, assays and 0-[2-(3-Tritylthiopropionylamino )ethyl]polyethylene gly-
methods of use of the mutant CocE polypeptides. col. 
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In some embodiments, a mutant CocE polypeptide is 
linked to a polyethylene glycol (PEG) polymer (i.e., PEGy-
lated). A PEG linked to a mutant CocE polypeptide can have 
a molecular weight as described above. For example, a PEG 
for linkage or coating a mutant CocE polypeptide can have 5 
a molecular weight of about 500 Daltons up to about 20,000 
Daltons ( or any of the molecular weights or ranges described 
above). 
PEGylation is understood as the process of covalent 
attachment of polyethylene glycol (PEG) polymer chains to 10 
another molecule, such as a drug or therapeutic protein. The 
structure of PEG is understood as H-(O----CH2----CH2 )n -
OH, where the parentheses contain the repeated element. A 
PEG can be polyethylene oxide (PEO) or polyoxyethylene 
(POE). PEG can have a molecular weight from about 300 15 
g/mol to about 10,000,000 g/mol. 
8 
raphy (IEX), hydrophobic interaction chromatography 
(HIC) and membranes or aqueous two phase systems (see 
generally, Fee 2003 "Protein conjugates purification and 
characterization", PEGylated Protein Drugs: Basic Science 
and Clinical Applications, Veronese, Ed. Birkhauser Pub-
lishing: Basel, 113-125; Fee 2003 Biotechnology and Bio-
engineering 82(2), 200-206). 
Polymer linkage to a mutant CocE polypeptide can be 
according to any method recognized in the art. For example, 
PEG can be conjugated to a primary amine or thiol. An 
amino group ( e.g. lysine) of a mutant CocE polypeptide can 
be conjugated to PEG by, e.g., alkylation or acylation. 
Alkylation can maintain a positively charged amine, 
whereas acylation can yield a neutral amide linkage. Acy-
lation can occur via an N-hydroxysuccinimide (NHS) acti-
vated carboxylated PEG. An azide functionalized PEG can 
allow Staudinger ligation or Huisgen dipolar cycloaddition 
techniques. The introduction of a different protecting group 
In some embodiments, a different form of PEG is used, 
according to the initiator used for the polymerization pro-
cess. For example, a monofunctional methyl ether PEG, or 
methoxypoly(ethylene glycol) (mPEG) can be used. 
PEGylation can be achieved by incubation of a reactive 
derivative of PEG with the target molecule, e.g., a mutant 
CocE described herein. Covalent attachment of PEG to a 
20 can be useful for macromolecular cross-linking agents and 
spacers. Mutant CocE polypeptide target moieties can be 
specifically addressed with an appropriate functionalized 
PEG linker. 
mutant CocE polypeptide can "mask" the polypeptide from A choice of suitable functional group for the PEG deriva-
tive can based on the type of available reactive group on the 
mutant CocE polypeptide that will be coupled to the PEG. 
For a mutant CocE polypeptide, reactive amino acids can 
include, for example, lysine, cysteine, histidine, arginine, 
aspartic acid, glutamic acid, serine, threonine, or tyrosine. 
a host's immune system (e.g., providing reduced immuno- 25 
genicity or antigenicity), or increase the hydrodynamic size 
(size in solution) of the mutant CocE polypeptide which can 
prolong its circulatory time ( e.g., by reducing renal clear-
ance). PEGylation can also provide increased water solubil-
ity. 
PEGylation can alter physiochemical properties of a 
mutant CocE polypeptide including changes in conforma-
tion, electrostatic binding, hydrophobicity, etc. These and 
other physical and chemical changes can increase systemic 
retention of the mutant CocE polypeptide. Also, PEGylation 35 
may influence the binding affinity of a mutant CocE poly-
peptide to cell receptors and may alter the absorption and 
distribution patterns. 
30 The N-terminal amino group and the C-terminal carboxylic 
acid can also be used as a site specific site by conjugation 
with aldehyde functional polymers. In some embodiments, a 
PEGylation can occur at a mutated position of the CocE 
PEGylation, by increasing the molecular weight of a 
molecule, such as a mutant CocE polypeptide, can impart 40 
significant pharmacological advantages over the unmodified 
form, including but not limited to: improved solubility; 
reduced dosage frequency, without diminished efficacy with 
potentially reduced toxicity; extended circulating life; 
increased drug stability; or enhanced protection from pro- 45 
teolytic degradation. A PEGylated mutant CocE polypeptide 
can have: increased water solubility; higher mobility in 
solution; lower toxicity; lower immunogenicity; ready clear-
ance from the body; or altered distribution in the body. 
PEGylation can include suitable functionalization of a 50 
PEG polymer at one or both terminals. PEGs that are 
activated at each terminus with the same reactive moiety are 
known as "homobifunctional", whereas if the functional 
groups present are different, then the PEG derivative is 
referred as "heterobifunctional" or "heterofunctional." The 55 
chemically active or activated derivatives of the PEG poly-
mer can be prepared to attach the PEG to a mutant CocE 
polypeptide. 
PEGylation can be according to a solution phase batch 
process or an on-colunm fed-batch process (see generally, 60 
Fee et al. 2006 Chemical Engineering Science 61(3), 924). 
For example, a batch process can involve mixing of reagents 
together in a suitable buffer solution, e.g., at a temperature 
between 4 and 6° C., followed by the separation and 
purification of the desired product using a suitable technique 65 
based on its physicochemical properties, including size 
exclusion chromatography (SEC), ion exchange chromatog-
polypeptide. For example, PEGylation can occur at one or 
more of mutations at C107, C429, C551, or C477 from SEQ 
ID NO: 1. As another example, PEGylation can occur at one 
or more of mutations at C107S, C429S, C551S, or C477S 
from SEQ ID NO: 1. 
A first generation PEG derivative can be formed by 
reacting a PEG polymer with a group that is reactive with 
hydroxyl groups, e.g., anhydrides, acid chlorides, chlorofor-
mates or carbonates. In the second generation PEGylation 
chemistry more efficient functional groups such as aldehyde, 
esters, amides etc. can be made available for conjugation. 
Heterobifunctional PEGs can be useful in linking two 
entities ( e.g., a mutant CocE polypeptide and another entity, 
or two mutant CocE polypeptides), where a hydrophilic, 
flexible and biocompatible spacer is needed. Exemplary end 
groups for heterobifunctional PEGs are maleimide, vinyl 
sulfones, pyridyl disulfide, amine, carboxylic acids and NHS 
esters. 
In some embodiments, PEGylation of a CocE polypeptide 
involves a homobifunctionalized, heterobifunctionalized, or 
mono-methoxy endcapped PEG. 
The shape of the PEG polymer can be branched, star 
shaped, Y shaped or comb shaped, where such shapes can 
reduce viscosity or lack of organ accumulation. Branched 
PEGs can have about three to about ten PEG chains ema-
nating from a central core group. Star PEGs can have about 
10 to about 100 PEG chains emanating from a central core 
group. Comb PEGs can have multiple PEG chains normally 
grafted onto a polymer backbone. 
Molecular Engineering 
The following definitions and methods are provided to 
better define the present invention and to guide those of 
ordinary skill in the art in the practice of the present 
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invention. Unless otherwise noted, terms are to be under-
stood according to conventional usage by those of ordinary 
skill in the relevant art. 
Molecular engineering can be as described in U.S. Pat. 
No. 8,318,156, issued 27 Nov. 2012, and incorporated herein 
by reference in its entirety. 
The terms "heterologous DNA sequence", "exogenous 
DNA segment" or "heterologous nucleic acid," as used 
herein, each refer to a sequence that originates from a source 
foreign to the particular host cell or, if from the same source, 
is modified from its original form. Thus, a heterologous gene 
in a host cell includes a gene that is endogenous to the 
particular host cell but has been modified through, for 
example, the use of DNA shuffling. The terms also include 
non-naturally occurring multiple copies of a naturally occur-
ring DNA sequence. Thus, the terms refer to a DNA segment 
that is foreign or heterologous to the cell, or homologous to 
the cell but in a position within the host cell nucleic acid in 
which the element is not ordinarily found. Exogenous DNA 
segments are expressed to yield exogenous polypeptides. A 
"homologous" DNA sequence is a DNA sequence that is 
naturally associated with a host cell into which it is intro-
duced. 
10 
transcribed sequence, which is also defined as position + 1. 
With respect to this site all other sequences of the gene and 
its controlling regions can be numbered. Downstream 
sequences (i.e., further protein encoding sequences in the 3' 
direction) can be denominated positive, while upstream 
sequences (mostly of the controlling regions in the 5' direc-
tion) are denominated negative. 
"Operably-linked" or "functionally linked" refers prefer-
ably to the association of nucleic acid sequences on a single 
10 
nucleic acid fragment so that the function of one is affected 
by the other. For example, a regulatory DNA sequence is 
said to be "operably linked to" or "associated with" a DNA 
sequence that codes for an RNA or a polypeptide if the two 
15 sequences are situated such that the regulatory DNA 
sequence affects expression of the coding DNA sequence 
(i.e., that the coding sequence or functional RNA is under 
the transcriptional control of the promoter). Coding 
sequences can be operably-linked to regulatory sequences in 
20 sense or antisense orientation. The two nucleic acid mol-
ecules may be part of a single contiguous nucleic acid 
molecule and may be adjacent. For example, a promoter is 
operably linked to a gene of interest if the promoter regulates 
or mediates transcription of the gene of interest in a cell. 
A "construct" is generally understood as any recombinant 
nucleic acid molecule such as a plasmid, cosmid, virus, 
autonomously replicating nucleic acid molecule, phage, or 
linear or circular single-stranded or double-stranded DNA or 
RNA nucleic acid molecule, derived from any source, 
Expression vector, expression construct, plasmid, or 
recombinant DNA construct is generally understood to refer 25 
to a nucleic acid that has been generated via human inter-
vention, including by recombinant means or direct chemical 
synthesis, with a series of specified nucleic acid elements 
that permit transcription or translation of a particular nucleic 
acid in, for example, a host cell. The expression vector can 30 capable of genomic integration or autonomous replication, 
comprising a nucleic acid molecule where one or more 
nucleic acid molecule has been operably linked. 
be part of a plasmid, virus, or nucleic acid fragment. 
Typically, the expression vector can include a nucleic acid to 
be transcribed operably linked to a promoter. 
A "promoter" is generally understood as a nucleic acid 
control sequence that directs transcription of a nucleic acid. 
An inducible promoter is generally understood as a promoter 
that mediates transcription of an operably linked gene in 
response to a particular stimulus. A promoter can include 
necessary nucleic acid sequences near the start site of 
transcription, such as, in the case of a polymerase II type 
promoter, a TATA element. A promoter can optionally 
include distal enhancer or repressor elements, which can be 
located as much as several thousand base pairs from the start 
site of transcription. 
A constructs of the present disclosure can contain a 
promoter operably linked to a transcribable nucleic acid 
35 molecule operably linked to a 3' transcription termination 
nucleic acid molecule. In addition, constructs can include 
but are not limited to additional regulatory nucleic acid 
molecules from, e.g., the 3'-untranslated region (3' UTR). 
Constructs can include but are not limited to the 5' untrans-
40 lated regions (5' UTR) of an mRNA nucleic acid molecule 
which can play an important role in translation initiation and 
can also be a genetic component in an expression construct. 
These additional upstream and downstream regulatory 
nucleic acid molecules may be derived from a source that is 
45 native or heterologous with respect to the other elements 
present on the promoter construct. 
A "transcribable nucleic acid molecule" as used herein 
refers to any nucleic acid molecule capable of being tran-
scribed into a RNA molecule. Methods are known for 
introducing constructs into a cell in such a manner that the 
transcribable nucleic acid molecule is transcribed into a 
functional mRNA molecule that is translated and therefore 50 
The term "transformation" refers to the transfer of a 
nucleic acid fragment into the genome of a host cell, 
resulting in genetically stable inheritance. Host cells con-
taining the transformed nucleic acid fragments are referred 
to as "transgenic" cells, and organisms comprising trans-
genic cells are referred to as "transgenic organisms". 
expressed as a protein product. Constructs may also be 
constructed to be capable of expressing antisense RNA 
molecules, in order to inhibit translation of a specific RNA 
molecule of interest. For the practice of the present disclo-
sure, conventional compositions and methods for preparing 
and using constructs and host cells are well known to one 
skilled in the art (see e.g., Sambrook and Russel (2006) 
Condensed Protocols from Molecular Cloning: A Labora-
tory Manual, Cold Spring Harbor Laboratory Press, ISBN-
"Transformed," "transgenic," and "recombinant" refer to 
a host cell or organism such as a bacterium, cyanobacterium, 
55 animal or a plant into which a heterologous nucleic acid 
molecule has been introduced. The nucleic acid molecule 
10: 0879697717; Ausubel et al. (2002) Short Protocols in 60 
Molecular Biology, 5th ed., Current Protocols, ISBN-10: 
0471250929; Sambrook and Russel (2001) Molecular Clon-
ing: A Laboratory Manual, 3d ed., Cold Spring Harbor 
Laboratory Press, ISBN-10: 0879695773; Elhai, J. and 
Wolk, C. P. 1988. Methods in Enzymology 167, 747-754). 65 
The "transcription start site" or "initiation site" is the 
position surrounding the first nucleotide that is part of the 
can be stably integrated into the genome as generally known 
in the art and disclosed (Sambrook 1989; Innis 1995; 
Gelfand 1995; Innis & Gelfand 1999). Known methods of 
PCR include, but are not limited to, methods using paired 
primers, nested primers, single specific primers, degenerate 
primers, gene-specific primers, vector-specific primers, par-
tially mismatched primers, and the like. The term "untrans-
formed" refers to normal cells that have not been through the 
transformation process. 
"Wild-type" refers to a virus or organism found in nature 
without any known mutation. 
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Design, generation, and testing of the variant nucleotides, 
and their encoded polypeptides, having the above required 
percent identities and retaining a required activity of the 
expressed protein is within the skill of the art. For example, 
directed evolution and rapid isolation of mutants can be 
according to methods described in references including, but 
not limited to, Link et al. (2007) Nature Reviews 5(9), 
680-688; Sanger et al. (1991) Gene 97(1), 119-123; 
Ghadessy et al. (2001) Proc Natl Acad Sci USA 98(8) 
4552-4557. Thus, one skilled in the art could generate a 10 
large number of nucleotide and/or polypeptide variants 
having, for example, at least 95-99% identity to the refer-
ence sequence described herein and screen such for desired 
phenotypes according to methods routine in the art. 
65° C. in the salt conditions of a 6xSSC, then the two 
sequences will not hybridize. On the other hand, if the 
melting temperature is above 65° C. in the same salt 
conditions, then the sequences will hybridize. In general, the 
melting temperature for any hybridized DNA.DNA 
sequence can be determined using the following formula: 
Tm, =81.5° C.+16.6(log10[Na+])+0.41(fraction G/C con-
tent)-0.63(% formamide )-(600/1). Furthermore, the Tm, of a 
DNA.DNA hybrid is decreased by 1-1.5° C. for every 1 % 
decrease in nucleotide identity (see e.g., Sambrook and 
Russel, 2006). 
Host cells can be transformed using a variety of standard 
techniques known to the art (see, e.g., Sambrook and Russel 
(2006) Condensed Protocols from Molecular Cloning: A 
Laboratory Manual, Cold Spring Harbor Laboratory Press, 
ISBN-10: 0879697717; Ausubel et al. (2002) Short Proto-
cols in Molecular Biology, 5th ed., Current Protocols, ISBN-
10: 0471250929; Sambrook and Russel (2001) Molecular 
Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor 
Nucleotide and/or amino acid sequence identity percent 15 
(%) is understood as the percentage of nucleotide or amino 
acid residues that are identical with nucleotide or amino acid 
residues in a candidate sequence in comparison to a refer-
ence sequence when the two sequences are aligned. To 
determine percent identity, sequences are aligned and if 
necessary, gaps are introduced to achieve the maximum 
percent sequence identity. Sequence alignment procedures 
20 Laboratory Press, ISBN-10: 0879695773; Elhai, J. and 
Wolk, C. P. 1988. Methods in Enzymology 167, 747-754). 
Such techniques include, but are not limited to, viral infec-
tion, calcium phosphate transfection, liposome-mediated 
transfection, microprojectile-mediated delivery, receptor-
to determine percent identity are well known to those of skill 
in the art. Often publicly available computer software such 
as BLAST, BLAST2, ALIGN2 or Megalign (DNASTAR) 
software is used to align sequences. Those skilled in the art 
can determine appropriate parameters for measuring align-
ment, including any algorithms needed to achieve maximal 
alignment over the full-length of the sequences being com-
pared. When sequences are aligned, the percent sequence 
identity of a given sequence A to, with, or against a given 
sequence B (which can alternatively be phrased as a given 
sequence A that has or comprises a certain percent sequence 
identity to, with, or against a given sequence B) can be 
calculated as: percent sequence identity=X/YlOO, where X 
is the number of residues scored as identical matches by the 
sequence alignment program's or algorithm's alignment of 
A and B and Y is the total number of residues in B. If the 
length of sequence A is not equal to the length of sequence 
B, the percent sequence identity of A to B will not equal the 
percent sequence identity of B to A. 
Generally, conservative substitutions can be made at any 
position so long as the required activity is retained. So-called 
conservative exchanges can be carried out in which the 
amino acid which is replaced has a similar property as the 
original amino acid, for example the exchange of Glu by 
Asp, Gin by Asn, Val by Ile, Leu by Ile, and Ser by Thr. 
Deletion is the replacement of an amino acid by a direct 
bond. Positions for deletions include the termini of a poly-
peptide and linkages between individual protein domains. 
Insertions are introductions of amino acids into the poly-
peptide chain, a direct bond formally being replaced by one 
or more amino acids. Amino acid sequence can be modu-
lated with the help of art-known computer simulation pro-
grams that can produce a polypeptide with, for example, 
improved activity or altered regulation. On the basis of this 
artificially generated polypeptide sequences, a correspond-
ing nucleic acid molecule coding for such a modulated 
polypeptide can be synthesized in-vitro using the specific 
codon-usage of the desired host cell. 
"Highly stringent hybridization conditions" are defined as 
hybridization at 65° C. in a 6xSSC buffer (i.e., 0.9 M sodium 
chloride and 0.09 M sodium citrate). Given these conditions, 
a determination can be made as to whether a given set of 
sequences will hybridize by calculating the melting tem-
perature (Tm) of a DNA duplex between the two sequences. 
If a particular duplex has a melting temperature lower than 
25 mediated uptake, cell fusion, electroporation, and the like. 
The transfected cells can be selected and propagated to 
provide recombinant host cells that comprise the expression 
vector stably integrated in the host cell genome. 
Exemplary nucleic acids which may be introduced to a 
30 host cell include, for example, DNA sequences or genes 
from another species, or even genes or sequences which 
originate with or are present in the same species, but are 
incorporated into recipient cells by genetic engineering 
methods. The term "exogenous" is also intended to refer to 
35 genes that are not normally present in the cell being trans-
formed, or perhaps simply not present in the form, structure, 
etc., as found in the transforming DNA segment or gene, or 
genes which are normally present and that one desires to 
express in a manner that differs from the natural expression 
40 pattern, e.g., to over-express. Thus, the term "exogenous" 
gene or DNA is intended to refer to any gene or DNA 
segment that is introduced into a recipient cell, regardless of 
whether a similar gene may already be present in such a cell. 
The type of DNA included in the exogenous DNA can 
45 include DNA which is already present in the cell, DNA from 
another individual of the same type of organism, DNA from 
a different organism, or a DNA generated externally, such as 
a DNA sequence containing an antisense message of a gene, 
or a DNA sequence encoding a synthetic or modified version 
50 of a gene. 
Host strains developed according to the approaches 
described herein can be evaluated by a number of means 
known in the art (see e.g., Studier (2005) Protein Expr Purif. 
41(1), 207-234; Gellissen, ed. (2005) Production ofRecom-
55 binant Proteins: Novel Microbial and Eukaryotic Expression 
Systems, Wiley-VCR, ISBN-10: 3527310363; Baneyx 
(2004) Protein Expression Technologies, Taylor & Francis, 
ISBN-10: 0954523253). 
Methods of down-regulation or silencing genes are known 
60 in the art. For example, expressed protein activity can be 
down-regulated or eliminated using antisense oligonucle-
otides, protein aptamers, nucleotide aptamers, and RNA 
interference (RNAi) (e.g., small interfering RNAs (sRNA), 
short hairpin RNA (shRNA), and micro RNAs (miRNA) 
65 (see e.g., Fanning and Symonds (2006) Handb Exp Phar-
macol. 173, 289-303G, describing hanmierhead ribozymes 
and small hairpin RNA; Helene, C., et al. (1992) Ann. N.Y. 
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Acad. Sci. 660, 27-36; Maher (1992) Bioassays 14(12): 
807-15, describing targeting deoxyribonucleotide 
sequences; Lee et al. (2006) Curr Opin Chem Biol. 10, 1-8, 
describing aptamers; Reynolds et al. (2004) Nature Biotech-
nology 22(3), 326-330, describing RNAi; Pushparaj and 
Melendez (2006) Clinical and Experimental Pharmacology 
and Physiology 33(5-6), 504-510, describing RNAi; Dillon 
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rate that will replace the amount of agent being metabolized 
and/or excreted from the body. The controlled-release of an 
agent can be stimulated by various inducers, e.g., change in 
pH, change in temperature, enzymes, water, or other physi-
ological conditions or molecules. 
et al. (2005) Annual Review of Physiology 67, 147-173, 
describing RN Ai; Dykxhoorn and Lieberman (2005) Annual 
Review of Medicine 56, 401-423, describing RNAi). RNAi 10 
molecules are commercially available from a variety of 
sources ( e.g., Ambion, TX; Sigma Aldrich, MO; Invitrogen). 
Several siRNA molecule design programs using a variety of 
algorithms are known to the art (see e.g., Cenix algorithm, 
Ambion; BLOCK-iT™ RNAi Designer, Invitrogen; siRNA 15 
Whitehead Institute Design Tools, Bioinformatics & 
Research Computing). Traits influential in defining optimal 
siRNA sequences include G/C content at the termini of the 
siRNAs, Tm of specific internal domains of the siRNA, 
siRNA length, position of the target sequence within the 20 
CDS (coding region), and nucleotide content of the 3' 
overhangs. 
Agents or compositions described herein can also be used 
in combination with other therapeutic modalities, as 
described further below. Thus, in addition to the therapies 
described herein, one may also provide to the subject other 
therapies known to be efficacious for treatment of the 
disease, disorder, or condition. 
Therapeutic Methods 
Another aspect of the invention is directed toward a 
catalytic degradation approach to anti-cocaine therapeutics. 
Provided are treatments, both prophylactic and therapeutic, 
of cocaine-induced conditions through the administration of 
mutant CocE polypeptides described herein to a subject in 
need thereof. The cocaine esterase variants of the invention 
hold significant clinical value because of their properties 
described herein, which include increased thermo stability or 
longer plasma half-life than known naturally occurring 
CocE. It is this increase in thermostability and plasma 
half-life that can provide a much more rapid response to the 
life-threatening symptoms of cocaine toxicity that sets the 
Formulation 
25 CocE variants of the present disclosure apart from other 
treatment options. 
The agents and compos1t10ns described herein can be 
formulated by any conventional manner using one or more 
pharmaceutically acceptable carriers or excipients as 
described in, for example, Remington's Pharmaceutical Sci-
ences (A. R. Gennaro, Ed.), 21st edition, ISBN: 0781746736 
(2005), incorporated herein by reference in its entirety. Such 
formulations will contain a therapeutically effective amount 30 
of a biologically active agent described herein, which can be 
Therapeutic methods can be as described in U.S. Pat. No. 
8,318,156, issued 27 Nov. 2012, and incorporated herein by 
reference in its entirety. 
Methods described herein are generally performed on a 
subject in need thereof. A cocaine-induced condition can 
include, but is not limited to, cocaine overdose, cocaine 
toxicity, and cocaine dependence and/or addiction. For 
example, the diagnosis of cocaine toxicity can include 
in purified form, together with a suitable amount of carrier 
so as to provide the form for proper administration to the 
subject. 
Formulation can be conducted as described in U.S. Pat. 
No. 8,318,156, issued 27 Nov. 2012, and incorporated herein 
by reference in its entirety. 
Formulation can include compounds disclosed in US App 
Pub. No. 2011/0142816, published on 16 Jun. 2011, and 
incorporated herein by reference in its entirety. 
The formulation should suit the mode of administration. 
The agents of use with the current disclosure can be formu-
lated by known methods for administration to a subject 
using several routes which include, but are not limited to, 
parenteral, pulmonary, oral, topical, intradermal, intramus-
cular, intraperitoneal, intravenous, subcutaneous, intranasal, 
epidural, ophthalmic, buccal, and rectal. The individual 
agents may also be administered in combination with one or 
more additional agents or together with other biologically 
active or biologically inert agents. Such biologically active 
or inert agents may be in fluid or mechanical communication 
with the agent(s) or attached to the agent(s) by ionic, 
covalent, Van der Waals, hydrophobic, hydrophilic or other 
physical forces. 
Controlled-release ( or sustained-release) preparations can 
be formulated to extend the activity of the mutant CocE 
polypeptide and reduce dosage frequency. Controlled-re-
lease preparations can also be used to effect the time of onset 
of action or other characteristics, such as blood levels of the 
agent, and consequently affect the occurrence of side effects. 
Controlled-release preparations can be designed to initially 
release an amount of mutant CocE polypeptide that produces 
the desired therapeutic effect, and gradually and continually 
release other amounts to maintain the level of therapeutic 
effect over an extended period of time. In order to maintain 
a near-constant level of mutant CocE polypeptide in the 
body, the agent can be released from the dosage form at a 
35 convulsions, grand-ma! seizures, cardiac arrest, myocardial 
infarction, cardiac arrhythmias, increased blood pressure, 
stroke, drug-induced psychosis, dissecting aneurysm, and 
increased myocardial oxygen demand. As another example, 
in the case of cocaine dependence or addiction, withdrawal 
40 symptoms can include subjective sensations of mild to 
severe dysphora, depression, anxiety, or irritability. 
A subject in need of the therapeutic methods described 
herein can be a subject having, diagnosed with, suspected of 
having, or at risk for developing a cocaine-induced condi-
45 tion. Subjects with an identified need of therapy include 
those with a diagnosed cocaine-induced condition, an indi-
cation of a cocaine-induced condition, and subjects who 
have been treated, are being treated, or will be treated for a 
cocaine-induced condition. A determination of the need for 
50 treatment will typically be assessed by a history and physical 
exam consistent with the disease or condition at issue. 
Diagnosis of the various conditions treatable by the methods 
described herein is within the skill of the art. The subject can 
be an animal subject, including a mammal, such as horses, 
55 cows, dogs, cats, sheep, pigs, mice, rats, monkeys, hamsters, 
guinea pigs, and chickens, and humans. For example, the 
subject can be a human subject. 
An effective amount of the mutant CocE polypeptides 
described herein is generally that which can reduce the 
60 cocaine-toxicity or the severity of a cocaine-induced condi-
tion. Reduction in severity includes, for example, an arrest 
or a decrease in symptoms, physiological indicators, bio-
chemical markers, or metabolic indicators. When used in the 
methods of the invention, a therapeutically effective amount 
65 of mutant CocE polypeptide described herein can be 
employed in pure form or, where such forms exist, in 
pharmaceutically acceptable salt form and with or without a 
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pharmaceutically acceptable excipient. For example, the 
mutant CocE polypeptides of the invention can be admin-
istered at a reasonable benefit/risk ratio applicable to any 
medical treatment, in an amount sufficient to substantially 
reduce the cocaine concentration in the blood or tissues of 
the subject. 
According to the methods described herein, administra-
tion can be parenteral, pulmonary, oral, topical, intradermal, 
intramuscular, intraperitoneal, intravenous, subcutaneous, 
intranasal, epidural, ophthalmic, buccal, or rectal adminis-
tration. 
Toxicity and therapeutic efficacy of compositions 
described herein can be determined by standard pharmaceu-
tical procedures in cell cultures or experimental animals for 
determining the LD50 (the dose lethal to 50% of the popu-
lation) and the ED50, (the dose therapeutically effective in 
50% of the population). The dose ratio between toxic and 
therapeutic effects is the therapeutic index that can be 
expressed as the ratio LD50/ED50 , where larger therapeutic 
indices are generally understood in the art to be optimal. 
The specific therapeutically effective dose level for any 
particular subject will depend upon a variety of factors 
including the disorder being treated and the severity of the 
disorder; activity of the specific compound employed; the 
specific composition employed; the age, body weight, gen-
eral health, sex and diet of the subject; the time of admin-
istration; the route of administration; the rate of excretion of 
the composition employed; the duration of the treatment; 
drugs used in combination or coincidental with the specific 
compound employed; and like factors well known in the 
medical arts (see e.g., Koda-Kimble et al. (2004) Applied 
Therapeutics: The Clinical Use of Drugs, Lippincott Wil-
liams & Wilkins, ISBN 0781748453; Winter (2003) Basic 
Clinical Pharmacokinetics, 4th ed., Lippincott Williams & 
Wilkins, ISBN 0781741475; Sharqel (2004) Applied Biop-
harmaceutics & Pharmacokinetics, McGraw-Hill/Appleton 
& Lange, ISBN 0071375503). For example, it is well within 
the skill of the art to start doses of the composition at levels 
lower than those required to achieve the desired therapeutic 
effect and to gradually increase the dosage until the desired 
effect is achieved. If desired, the effective daily dose may be 
divided into multiple doses for purposes of administration. 
Consequently, single dose compositions may contain such 
amounts or submultiples thereof to make up the daily dose. 
16 
herein can be employed in pure form or, where such forms 
exist, in pharmaceutically acceptable salt form and with or 
without a pharmaceutically acceptable excipient. For 
example, the compounds of the present disclosure can be 
administered, at a reasonable benefit/risk ratio applicable to 
any medical treatment, in a sufficient amount to substantially 
reduce the cocaine concentration in the blood and/or tissues 
of the subject. 
The amount of a composition described herein that can be 
10 combined with a pharmaceutically acceptable carrier to 
produce a single dosage form will vary depending upon the 
host treated and the particular mode of administration. It will 
be appreciated by those skilled in the art that the unit content 
of agent contained in an individual dose of each dosage form 
15 need not in itself constitute a therapeutically effective 
amount, as the necessary therapeutically effective amount 
could be reached by administration of a number of indi-
vidual doses. Agent administration can occur as a single 
event or over a time course of treatment. For example, an 
20 agent can be administered daily, weekly, bi-weekly, or 
monthly. For some conditions, treatment could extend from 
several weeks to several months or even a year or more. 
Mutant CocE polypeptides described herein can also be 
used in combination with other therapeutic modalities. Thus, 
25 in addition to the therapies described herein, one can also 
provide to the subject other therapies known to be effica-
cious for particular cocaine-induced conditions. 
A mutant CocE polypeptide can be administered simul-
taneously or sequentially with another agent, such as an 
30 antibiotic, an antiinflammatory, or another agent. For 
example, a mutant CocE polypeptide can be administered 
simultaneously with another agent, such as an antibiotic or 
an antiinflammatory. Simultaneous administration can occur 
through administration of separate compositions, each con-
35 taining one or more of a mutant CocE polypeptide, an 
antibiotic, an antiinflammatory, or another agent. Simulta-
neous administration can occur through administration of 
one composition containing two or more of a mutant CocE 
polypeptide, an antibiotic, an antiinflannnatory, or another 
40 agent. A mutant CocE polypeptide can be administered 
sequentially with an antibiotic, an antiinflammatory, or 
another agent. For example, a mutant CocE polypeptide can 
be administered before or after administration of an antibi-
otic, an antiinflannnatory, or another agent. 
It will be understood, however, that the total daily usage of 45 
the compounds and compositions of the present disclosure 
will be decided by an attending physician within the scope 
Administration 
Agents and compositions described herein can be admin-
istered according to methods described herein in a variety of 
means known to the art. The agents and composition can be 
used therapeutically either as exogenous materials or as 
endogenous materials. Exogenous agents are those produced 
or manufactured outside of the body and administered to the 
of sound medical judgment. 
Again, each of the states, diseases, disorders, and condi-
tions, described herein, as well as others, can benefit from 50 
compositions and methods described herein. Generally, 
treating a state, disease, disorder, or condition includes 
preventing or delaying the appearance of clinical symptoms 
body. Endogenous agents are those produced or manufac-
tured inside the body by some type of device (biologic or 
other) for delivery within or to other organs in the body. 
Administration can be as described in U.S. Pat. No. 
8,318,156, issued 27 Nov. 2012, and incorporated herein by 
reference in its entirety. 
in a mammal that may be afflicted with or predisposed to the 
state, disease, disorder, or condition but does not yet expe- 55 
rience or display clinical or subclinical symptoms thereof. 
Treating can also include inhibiting the state, disease, dis-
order, or condition, e.g., arresting or reducing the develop-
ment of the disease or at least one clinical or subclinical 
symptom thereof. Furthermore, treating can include reliev-
ing the disease, e.g., causing regression of the state, disease, 
disorder, or condition or at least one of its clinical or 
subclinical symptoms. A benefit to a subject to be treated can 
As discussed above, administration can be parenteral, 
pulmonary, oral, topical, intradermal, intramuscular, intrap-
60 eritoneal, intravenous, subcutaneous, intranasal, epidural, 
ophthalmic, buccal, or rectal administration. 
be either statistically significant or at least perceptible to the 
subject or to a physician. 
When used in the treatments described herein, a thera-
peutically effective amount of a mutant CocE described 
Agents and compositions described herein can be admin-
istered in a variety of methods well known in the arts. 
Administration can include, for example, methods involving 
65 oral ingestion, direct injection (e.g., systemic or stereotac-
tic ), implantation of cells engineered to secrete the factor of 
interest, drug-releasing biomaterials, polymer matrices, gels, 
US 10,160,960 B2 
17 18 
35-51), hydrogels (see generally, Sakiyama et al. (2001) 
FASEB J. 15, 1300-1302), polymeric implants (see gener-
ally, Teng et al (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 
3024-3029), smart ploymeric carriers (see generally, Stayton 
et al. (2005) Orthod Craniofacial Res 8, 219-225; Wu et al. 
(2005) Nature Biotech (2005) 23(9), 1137-1146), and lipo-
somes (see e.g., Galovic et al. (2002) Eur. J. Pharm. Sci. 15, 
441-448; Wagner et al. (2002) J. Liposome Res. 12, 259-
270). In some embodiments, the mutant CocE polypeptide 
permeable membranes, osmotic systems, multilayer coat-
ings, microparticles, implantable matrix devices, mini-os-
motic pumps, implantable pumps, injectable gels and hydro-
gels, liposomes, micelles (e.g., up to 30 µm), nanospheres 
(e.g., less than 1 µm), microspheres (e.g., 1-100 µm), res-
ervoir devices, a combination of any of the above, or other 
suitable delivery vehicles to provide the desired release 
profile in varying proportions. Other methods of controlled-
release delivery of agents or compositions will be known to 
the skilled artisan and are within the scope of the present 
disclosure. 
10 can be encapsulated in a red blood cell. 
Screening 
Also provided are methods for screening. 
Another aspect of the invention is directed toward screen-
ing methods for the generation, identification, and purifica-
Pulmonary delivery of macromolecules, such as mutant 
CocE polypeptides, can provide relatively easy, non-inva-
sive administration to the circulatory system for systemic 
distribution (see e.g., Cryan (2004) AAPS J. 7(1) article 4, 
E20-41, providing a review of pulmonary delivery technol-
ogy). Advantages of pulmonary delivery include noninva-
siveness, large surface area for absorption (-7 5 m2 ), thin 
(-0.1 to 0.5 µm) alveolar epithelium permitting rapid 
absorption, absence of first pass metabolism, decreased 
proteolytic activity, rapid onset of action, and high bioavail-
ablity. Various inhalation delivery devices, such as metered-
dose inhalers, nebulizers, and dry-powder inhalers, that can 
15 tion of mutant CocE polypeptides. Generally, mutant CocE 
polypeptides can be initially designed according to the 
approaches described above. Such designed polypeptides 
can then be screened for preferred characteristics, such as 
retention of hydrolytic efficiency, increased thermo stability, 
20 increased plasma-half-life, or reduced antigenicity. Also, 
random mutant CocE polypeptides can be screened for the 
desired characteristics. 
be used to deliver the biomolecules described herein are 
known to the art (e.g., AErx (Aradigm, CA); Respimat 25 
(Boehringer, Germany); AeroDose (Aerogen Inc., CA)). Dry 
powder inhalation devices are particularly preferred for 
pulmonary delivery of protein-based agents ( e.g., Spinhaler 
(Fisons Pharmaceuticals, NY); Rotohaler (GSK, NC); Dis-
khaler (GSK, NC); Spiros (Dura Pharmaceuticals, CA); 30 
Nektar (Nektar Pharmaceuticals, CA)). 
Delivery systems may include, for example, an infusion 
pump which may be used to administer the agent or com-
position in a manner similar to that used for delivering 
insulin or chemotherapy to specific organs or tumors. Typi- 35 
cally, using such a system, an agent or composition can be 
administered in combination with a biodegradable, biocom-
patible polymeric implant that releases the agent over a 
controlled period of time at a selected site. Examples of 
polymeric materials include polyanhydrides, polyorthoe- 40 
sters, polyglycolic acid, polylactic acid, polyethylene vinyl 
acetate, and copolymers and combinations thereof. In addi-
tion, a controlled release system can be placed in proximity 
Detection methods to screen for mutants encompass a 
wide variety of techniques. The following is an exemplary 
surmnary of a generic protocol. Nucleic acid encoding the 
mutant CocE polypeptides (generated, for example, through 
rational design, random mutagenesis, or host mutagensis) is 
transformed into an appropriate expression host (for 
example, E. coli cells such as E. coli BL21 Gold (Strata-
gene )), and expression of the mutant polypeptide is induced 
according to standard protocols (e.g. by IPTG). Expression 
is performed at temperatures to produce optimal protein 
expression (e.g., 16° C. for CocE) for a pre-determined 
period of time ( e.g., anywhere from 30 minutes to 24 hours 
or longer). Alternatively, expression is performed at an 
elevated temperature (for example, the elevated temperature 
can be at least about 35° C., at least about 36° C., at least 
about 37° C., at least about 38° C., at least about 39° C., at 
least about 40° C., or even higher). Preferably, the elevated 
temperature at which mutated CocE polypeptide is 
expressed is 37° C. Around this temperature, wild-type 
CocE polypeptide partitions almost exclusively into inclu-
sion bodies. Cells containing the expressed mutant polypep-
tides are screened for the presence of thermostable variants of a therapeutic target, thus requiring only a fraction of a 
systemic dosage. 45 of CocE. 
Agents can be encapsulated and administered in a variety 
of carrier delivery systems. Examples of carrier delivery 
systems include microspheres, hydrogels, polymeric 
implants, smart polymeric carriers, and liposomes (see gen-
erally, Uchegbu and Schatzlein, eds. (2006) Polymers in 50 
Drug Delivery, CRC, ISBN-10: 0849325331). Carrier-based 
systems for molecular or biomolecular agent delivery can: 
provide for intracellular delivery; tailor biomolecule/agent 
release rates; increase the proportion of biomolecule that 
reaches its site of action; improve the transport of the drug 55 
to its site of action; allow colocalized deposition with other 
agents or excipients; improve the stability of the agent in 
vivo; prolong the residence time of the agent at its site of 
action by reducing clearance; decrease the nonspecific deliv-
ery of the agent to nontarget tissues; decrease irritation 60 
caused by the agent; decrease toxicity due to high initial 
doses of the agent; alter the immunogenicity of the agent; 
decrease dosage frequency, improve taste of the product; or 
improve shelf life of the product. 
Examples of carrier delivery systems for with mutant 65 
CocE polypeptides described herein include microspheres 
(see e.g., Yarde & Pack (2004) Expert Opin. Biol. 4(1) 
Screening for the presence of thermostable variants of 
CocE generally involves either direct measurement on cul-
tured cells, on cell lysates, or following cellular disruption 
and isolation of the mutant CocE polypeptide. Cellular 
disruption can include osmotic shock, chemical lysis, soni-
ciation, and/or homogenization, and isolation of the mutant 
polypeptide can be obtained through numerous methods 
including either direct absorption to a matrix or affinity 
absorption through the use of anti-cocaine antibodies or 
fusion-protein specific capture systems. Suitable matrix for 
absorption includes nitrocellulose paper, filters, untreated or 
affinity-treated microtiter plates, agarose or sepharose res-
ins, and/or affinity-coated tips. 
The esterase activity of the cultured cells or isolated 
mutant polypeptide can be subsequently measured at one or 
more temperatures to determine the thermostability of the 
mutants. The temperature at which the activity assay is 
performed determines the degree of thermostability detec-
tion. Thus, while the final mutants will preferably have a 
melting temperature of 45° C. or higher (as determined by, 
for example, circular dichroism), often, the initial screening 
at 45° C. will not find active enzymes. Rather, several cycles 
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Protocols, ISBN-10: 0471250929; Sambrook and Russel 
(2001) Molecular Cloning: A Laboratory Manual, 3d ed., 
Cold Spring Harbor Laboratory Press, ISBN-10: 
0879695773; Elhai, J. and Wolk, C. P. 1988. Methods in 
Enzymology 167, 747-754; Studier (2005) Protein Expr 
Purif. 41(1), 207-234; Gellissen, ed. (2005) Production of 
Recombinant Proteins: Novel Microbial and Eukaryotic 
Expression Systems, Wiley-VCR, ISBN-10: 3527310363; 
Baneyx (2004) Protein Expression Technologies, Taylor & 
of mutagenesis and screening at subsequently increasing 
temperatures can be performed to achieve thermostable 
mutants. Thus, initial screening can be performed at 30° C., 
and after further cycles of mutagenesis, screening can be 
performed with incrementally increasing temperatures (for 
example, 34° C., 37° C., 40° C., 42.5° C., 45° C., etc.), until 
a mutant of suitable thermostability is achieved. The incre-
mental temperature increases are determined empirically 
during the procedure, and are affected by the number of hits 
at particular temperatures and the determined Tm of the 
generated mutants. 
10 Francis, ISBN-10: 0954523253). 
Screening can be conducted as described in U.S. Pat. No. 
8,318,156, issued 27 Nov. 2012, and incorporated herein by 
reference in its entirety. 
Definitions and methods described herein are provided to 
better define the present disclosure and to guide those of 
ordinary skill in the art in the practice of the present 
disclosure. Unless otherwise noted, terms are to be under-
Kits 
Also provided are kits. Such kits can include an agent or 
composition described herein and, in certain embodiments, 
instructions for administration. Such kits can facilitate per-
formance of the methods described herein. When supplied as 
15 stood according to conventional usage by those of ordinary 
skill in the relevant art. 
In some embodiments, numbers expressing quantities of 
ingredients, properties such as molecular weight, reaction 
conditions, and so forth, used to describe and claim certain 
embodiments of the present disclosure are to be understood 
as being modified in some instances by the term "about." In 
some embodiments, the term "about" is used to indicate that 
a value includes the standard deviation of the mean for the 
device or method being employed to determine the value. In 
some embodiments, the numerical parameters set forth in 
the written description and attached claims are approxima-
tions that can vary depending upon the desired properties 
sought to be obtained by a particular embodiment. In some 
embodiments, the numerical parameters should be construed 
a kit, the different components of the composition can be 20 
packaged in separate containers and admixed immediately 
before use. Components include, but are not limited to a 
mutant CocE polypeptide. Such packaging of the compo-
nents separately can, if desired, be presented in a pack or 
dispenser device which may contain one or more unit dosage 25 
forms containing the composition. The pack may, for 
example, comprise metal or plastic foil such as a blister 
pack. Such packaging of the components separately can 
also, in certain instances, permit long-term storage without 
losing activity of the components. 30 in light of the number of reported significant digits and by 
applying ordinary rounding techniques. Notwithstanding 
that the numerical ranges and parameters setting forth the 
broad scope of some embodiments of the present disclosure 
Kits may also include reagents in separate containers such 
as, for example, sterile water or saline to be added to a 
lyophilized active component packaged separately. For 
example, sealed glass ampules may contain a lyophilized 
component and in a separate ampule, sterile water, sterile 35 
saline or sterile each of which has been packaged under a 
neutral non-reacting gas, such as nitrogen. Ampules may 
consist of any suitable material, such as glass, organic 
polymers, such as polycarbonate, polystyrene, ceramic, 
metal or any other material typically employed to hold 40 
reagents. Other examples of suitable containers include 
bottles that may be fabricated from similar substances as 
ampules, and envelopes that may consist of foil-lined inte-
riors, such as aluminum or an alloy. Other containers include 
test tubes, vials, flasks, bottles, syringes, and the like. 45 
Containers may have a sterile access port, such as a bottle 
having a stopper that can be pierced by a hypodermic 
injection needle. Other containers may have two compart-
ments that are separated by a readily removable membrane 
that upon removal permits the components to mix. Remov- 50 
able membranes may be glass, plastic, rubber, and the like. 
In certain embodiments, kits can be supplied with instruc-
tional materials. Instructions may be printed on paper or 
other substrate, and/or may be supplied as an electronic-
readable medium, such as a floppy disc, mini-CD-ROM, 55 
CD-ROM, DVD-ROM, Zip disc, videotape, audio tape, and 
the like. Detailed instructions may not be physically asso-
ciated with the kit; instead, a user may be directed to an 
Internet web site specified by the manufacturer or distributor 
are approximations, the numerical values set forth in the 
specific examples are reported as precisely as practicable. 
The numerical values presented in some embodiments of the 
present disclosure may contain certain errors necessarily 
resulting from the standard deviation found in their respec-
tive testing measurements. The recitation of ranges of values 
herein is merely intended to serve as a shorthand method of 
referring individually to each separate value falling within 
the range. Unless otherwise indicated herein, each individual 
value is incorporated into the specification as if it were 
individually recited herein. 
In some embodiments, the terms "a" and "an" and "the" 
and similar references used in the context of describing a 
particular embodiment ( especially in the context of certain 
of the following claims) can be construed to cover both the 
singular and the plural, unless specifically noted otherwise. 
In some embodiments, the term "or" as used herein, includ-
ing the claims, is used to mean "and/or" unless explicitly 
indicated to refer to alternatives only or the alternatives are 
mutually exclusive. 
The terms "comprise," "have" and "include" are open-
ended linking verbs. Any forms or tenses of one or more of 
these verbs, such as "comprises," "comprising," "has," 
"having," "includes" and "including," are also open-ended. 
For example, any method that "comprises," "has" or 
"includes" one or more steps is not limited to possessing 
of the kit. 60 only those one or more steps and can also cover other 
unlisted steps. Similarly, any composition or device that 
"comprises," "has" or "includes" one or more features is not 
limited to possessing only those one or more features and 
can cover other unlisted features. 
Compositions and methods described herein utilizing 
molecular biology protocols can be according to a variety of 
standard techniques known to the art (see, e.g., Sambrook 
and Russel (2006) Condensed Protocols from Molecular 
Cloning: A Laboratory Manual, Cold Spring Harbor Labo- 65 
ratory Press, ISBN-10: 0879697717; Ausubel et al. (2002) 
Short Protocols in Molecular Biology, 5th ed., Current 
All methods described herein can be performed in any 
suitable order unless otherwise indicated herein or otherwise 
clearly contradicted by context. The use of any and all 
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examples, or exemplary language ( e.g. "such as") provided 
with respect to certain embodiments herein is intended 
merely to better illuminate the present disclosure and does 
not pose a limitation on the scope of the present disclosure 
otherwise claimed. No language in the specification should 
be construed as indicating any non-claimed element essen-
tial to the practice of the present disclosure. 
22 
-continued 
GPWSHSNLTGRNADRKFGIAATYPIQEATTMHKAFFDRHLRGETDAL 
AGVPKVRLFVMGIDEWRDETDWPLPDTAYTPFYLGGSGAANTSTGGG 
TLSTSISGTESADTYLYDPADPVPSLGGTLLFHNGDNGPADQRPIHD 
RDDVLfYSTEVLTDPVEVTGTVSARLFVSSSAVDTDFTAKLVDVFPD 
GRAIALCDGIVRMRYRETLVNPTLIEAGEIYEVAIDMLATSNVFLPG Groupings of alternative elements or embodiments of the 
present disclosure disclosed herein are not to be construed as 
limitations. Each group member can be referred to and 
claimed individually or in any combination with other 
members of the group or other elements found herein. One 
10 HRIMVQVSSSNFPKYDRNSNTGGVIAREQLEEMfTAVNRIHRGPEHP 
SHIVLPIIKR 
Example 2: CocE MUTANTS 
or more members of a group can be included in, or deleted 
from, a group for reasons of convenience or patentability. 
When any such inclusion or deletion occurs, the specifica- 15 
tion is herein deemed to contain the group as modified thus 
fulfilling the written description of all Markush groups used The following example describes amino acid replace-
ments in CocE and activity thereof. The following cysteine-
mutated CocE mutants were fully sequenced and the activity 
20 tested (see e.g., FIG. 3A-E): 
in the appended claims. 
Citation of a reference herein shall not be construed as an 
admission that such is prior art to the present disclosure. 
Having described the present disclosure in detail, it will 
be apparent that modifications, variations, and equivalent 
embodiments are possible without departing the scope of the 
present disclosure defined in the appended claims. Further-
more, it should be appreciated that all examples in the 25 
present disclosure are provided as non-limiting examples. 
EXAMPLES 
The following non-limiting examples are provided to 30 
further illustrate the present disclosure. It should be appre-
ciated by those of skill in the art that the techniques 
disclosed in the examples that follow represent approaches 
the inventors have found function well in the practice of the 
present disclosure, and thus can be considered to constitute 35 
examples of modes for its practice. However, those of skill 
NAME 
Lys 2: 
Ala32S: 
AsplS: 
Thr12: 
Val434: 
SUBSTITUTIONS 
C107S, C429S; 
C107S, C429S, A32SC; 
DISC, C107S, C429S; 
C107S, C429S, T436C; and 
C107S, C429S, V434C. 
Activity was also tested for the following CocE mutants: 
L163V; V121 D; S167A; S167A/W52L; Q123E; S159A; 
T122A; S140A; T172R; S265A; W220A; A193D; and 
Y532F. 
S167A mutant results did not show enhanced activity 
compared to wild-type. S159Amutant showed some degree 
of thermostability. T122A showed some degree of thermo-
stability. Tl 72R mutant showed enhanced activity compared 
to WT. 
in the art should, in light of the present disclosure, appreciate 
that many changes can be made in the specific embodiments 
that are disclosed and still obtain a like or similar result 
40 The following mutations were also envisioned as amino 
:~t~~~~!?arting from the spirit and scope of the present acid replacements: S265A; W220A; A193D; and Y532F. 
Example 1: CocE Sequence 
The following example shows the sequence listing for 45 
bacterial CocE (Gene cloning and nucleotide sequencing 
and properties of a cocaine esterase from Rhodococcus sp. 
strain MB!. Bresler M. M., Rosser S. J., Basran A., Bruce 
N. C. Appl. Environ. Microbial. 66:904-908(2000)). Cyste-
ine positions 107, 429, 477, and 551 are underlined below in 50 
SEQ ID NO: 1. 
>splQ9L9D7ICOCE_RHOSM Cocaine esterase 
OS - Rhodococcus sp. (strain MBl Bresler) 
GN - cocE PE - 1 SV - 1, 
SEQ ID NO, 1 
MVDGNYSVASNVMVPMRDGVRLAVDLYRPDADGPVPVLLVRNPYDKF 
DVFAWSTQSTNWLEFVRDGYAVVIQDTRGLFASEGEFVPHVDDEADA 
EDTLSWILEQAWfDGNVGMFGVSYLGVTQWQAAVSGVGGLKAIAPSM 
ASADLYRAPWYGPGGALSVEALLGWSALIGTGLITSRSDARPEDAAD 
FVQLAAILNDVAGAASVTPLAEQPLLGRLIPWVIDQVVDHPDNDESW 
QSISLFERLGGLATPALITAGWYDGFVGESLRTFVAVKDNADARLVV 
55 
60 
65 
Example 3: Generation of Mutants 
The following example describes various mutants. 
Double 107/429 mutants were generated by primer exten-
sion, replacing Cys with Ala (see e.g., FIG. 4). Additional 
mutations were further studied and tested for activity (see 
e.g., FIG. 5 and FIG. 6). Results are shown in TABLE 1. 
TABLE 1 
CocE Mutants and Cocaine Esterase Activity 
Cocaine Esterase Activity 
Mutant Name Substitutions relative to WT 
2 Ala#2 C107A/C429A None 
AS C107A Low 
BS C429A Lower 
RetWT-6 C107C/C429S Ok 
1 Ser-3 (107) C107S Ok 
2 Ser#2 C107S/C429S Ok 
Lys#2 C107S/C429S/K315C None 
Thr#12 C107S/C429S/T429C None 
Asp#4 C107S/C429S/Dl SC None 
Val434 #6 C107S/C429SN434C Tbd 
Ala32S #2 C107S/C429S/A32SC Tbd 
US 10,160,960 B2 
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<160> NUMBER OF SEQ ID NOS, 1 
<210> SEQ ID NO 1 
<211> LENGTH, 574 
<212> TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Rhodococcus sp. strain MBl 
<400> SEQUENCE, 1 
Met Val Asp Gly Asn Tyr Ser Val Ala Ser Asn Val Met Val Pro Met 
1 5 10 15 
Arg Asp Gly Val Arg Leu Ala Val Asp Leu Tyr Arg Pro Asp Ala Asp 
20 25 30 
Gly Pro Val Pro Val Leu Leu Val Arg Asn Pro Tyr Asp Lys Phe Asp 
35 40 45 
Val Phe Ala Trp Ser Thr Gln Ser Thr Asn Trp Leu Glu Phe Val Arg 
50 55 60 
Asp Gly Tyr Ala Val Val Ile Gln Asp Thr Arg Gly Leu Phe Ala Ser 
65 70 75 80 
Glu Gly Glu Phe Val Pro His Val Asp Asp Glu Ala Asp Ala Glu Asp 
85 90 95 
Thr Leu Ser Trp Ile Leu Glu Gln Ala Trp Cys Asp Gly Asn Val Gly 
100 105 110 
Met Phe Gly Val Ser Tyr Leu Gly Val Thr Gln Trp Gln Ala Ala Val 
115 120 125 
Ser Gly Val Gly Gly Leu Lys Ala Ile Ala Pro Ser Met Ala Ser Ala 
130 135 140 
Asp Leu Tyr Arg Ala Pro Trp Tyr Gly Pro Gly Gly Ala Leu Ser Val 
145 150 155 160 
Glu Ala Leu Leu Gly Trp Ser Ala Leu Ile Gly Thr Gly Leu Ile Thr 
165 170 175 
Ser Arg Ser Asp Ala Arg Pro Glu Asp Ala Ala Asp Phe Val Gln Leu 
180 185 190 
Ala Ala Ile Leu Asn Asp Val Ala Gly Ala Ala Ser Val Thr Pro Leu 
195 200 205 
Ala Glu Gln Pro Leu Leu Gly Arg Leu Ile Pro Trp Val Ile Asp Gln 
210 215 220 
Val Val Asp His Pro Asp Asn Asp Glu Ser Trp Gln Ser Ile Ser Leu 
225 230 235 240 
Phe Glu Arg Leu Gly Gly Leu Ala Thr Pro Ala Leu Ile Thr Ala Gly 
245 250 255 
Trp Tyr Asp Gly Phe Val Gly Glu Ser Leu Arg Thr Phe Val Ala Val 
260 265 270 
Lys Asp Asn Ala Asp Ala Arg Leu Val Val Gly Pro Trp Ser His Ser 
275 280 285 
Asn Leu Thr Gly Arg Asn Ala Asp Arg Lys Phe Gly Ile Ala Ala Thr 
290 295 300 
Tyr Pro Ile Gln Glu Ala Thr Thr Met His Lys Ala Phe Phe Asp Arg 
305 310 315 320 
His Leu Arg Gly Glu Thr Asp Ala Leu Ala Gly Val Pro Lys Val Arg 
325 330 335 
Leu Phe Val Met Gly Ile Asp Glu Trp Arg Asp Glu Thr Asp Trp Pro 
340 345 350 
Leu Pro Asp Thr Ala Tyr Thr Pro Phe Tyr Leu Gly Gly Ser Gly Ala 
355 360 365 
24 
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-continued 
Ala Asn Thr Ser Thr Gly Gly Gly Thr Leu Ser Thr Ser Ile Ser Gly 
370 375 380 
Thr Glu Ser Ala Asp Thr Tyr Leu Tyr Asp Pro Ala Asp Pro Val Pro 
385 390 395 400 
Ser Leu Gly Gly Thr Leu Leu Phe His Asn Gly Asp Asn Gly Pro Ala 
405 410 415 
Asp Gln Arg Pro Ile His Asp Arg Asp Asp Val Leu Cys Tyr Ser Thr 
420 425 430 
Glu Val Leu Thr Asp Pro Val Glu Val Thr Gly Thr Val Ser Ala Arg 
435 440 445 
Leu Phe Val Ser Ser Ser Ala Val Asp Thr Asp Phe Thr Ala Lys Leu 
450 455 460 
Val Asp Val Phe Pro Asp Gly Arg Ala Ile Ala Leu Cys Asp Gly Ile 
465 470 475 480 
Val Arg Met Arg Tyr Arg Glu Thr Leu Val Asn Pro Thr Leu Ile Glu 
485 490 495 
Ala Gly Glu Ile Tyr Glu Val Ala Ile Asp Met Leu Ala Thr Ser Asn 
500 505 510 
Val Phe Leu Pro Gly His Arg Ile Met Val Gln Val Ser Ser Ser Asn 
515 520 525 
Phe Pro Lys Tyr Asp Arg Asn Ser Asn Thr Gly Gly Val Ile Ala Arg 
530 535 540 
Glu Gln Leu Glu Glu Met Cys Thr Ala Val Asn Arg Ile His Arg Gly 
545 550 555 560 
Pro Glu His Pro Ser His Ile Val Leu Pro Ile Ile Lys Arg 
565 570 
The invention claimed is: 
1. A composition comprising an isolated mutant cocaine 
esterase (CocE) polypeptide comprising: 
35 
an amino acid sequence having at least about 95% 
sequence identity to SEQ ID NO: 1 having-two or more 40 
substitutions at an amino acid position selected from 
the group consisting of C107, C429, and C551; 
wherein the polypeptide has cocaine esterase activity. 
2. The composition of claim 1, wherein the-two or more 
substitutions are selected from the group consisting of 45 
C107S, C429S, and C551S. 
3. The composition of claim 2, wherein the-two or more 
substitutions comprise C107S and C429S. 
Gl 71Q/Tl 72R/Gl 73Q, Tl 72R/G173Q-Tl 76-G-G-Dl85; 
Gl 73Q-Il 75-G-G-A186; Gl 73Q-Tl 76-G-G-Dl85; I175-G-
G-A186; Tl 76-G-G-Dl85; wt-Il 75-G-Dl85; wt-Tl 76-G-
G-Dl85; F189A/T172R; R75K; F78C; F78R;A79K;A79R; 
Y118S; V121Y; L164K; W166R; I170V; G173Q; T176R; 
S177C; K315C; G171S; D180K; P183K; F78C/S177C; and 
Y118S/V121Y. 
7. The composition of claim 1, wherein the CocE poly-
peptide further comprises one or more substitutions selected 
from the group consisting of: R41I; N42V; Y44F; D45R; 
F47R; K46A; S56G; T74S; F84Y; S117A; L119A; G173Q; 
S140A; L146P; A149S; Y152H; S159A; V160A; L163V; 
L169K; G171A; T172R; G173A; L174R; S177Q; A181K; 
S179R; R182K; F189A; F189K; F189L; V190K; Q191K; 
A193D; A194K; A194R; N197K; I218L; W220A; V225I; 4. The composition of claim 1, wherein the-two or more 
substitutions are not C107A, C429A, or C551A. 
5. The composition of claim 1, wherein the CocE poly-
peptide further comprises one or more of a substitution, 
addition, or deletion selected from the group consisting of 
A328C, DISC, T436C, V434C, L163V; V121D; S167A, 
W52L, Q123E, S159A, T122A, S140A, T172R, G173Q, 
S265A, W220A, A193D, and Y532F. 
50 T254R; V262L; S265A; W285T; A310D; C477T; L508G; 
K531A; Y532F; D533S; Tl 72R/Gl 73Q; Tl 72R/A193D; 
T172R/F189K; T172R/G173Q-I175-G-G-A186; G171Q/ 
Tl 72R/G 173Q, Tl 72R/G 173Q-Tl 76-G-G-Dl 85; G 173Q-
Il 75-G-G-Al 86; G173Q-T176-G-G-Dl85; 1175-G-G-
55 A186; T176-G-G-Dl85; wt-I175-G-Dl85; wt-T176-G-G-
D185; and F189A/T172R. 
8. The composition of claim 1, wherein the CocE poly-
peptide further comprises one or more substitutions selected 
from the group consisting of: R75K; F78C; F78R; A79K; 
60 A79R; Y118S; V121Y; L164K; W166R; I170V; G173Q; 
T176R; S177C; K315C; G171S; D180K; P183K; F78C/ 
S177C; and Y118S/V121Y. 
6. The composition of claim 1, wherein the CocE poly-
peptide further comprises one or more substitutions selected 
from the group consisting of: R41 I; N42V; Y44F; D45R; 
F47R; K46A; S56G; T74S; F84Y; S117A; L119A; G173Q; 
S140A; L146P; A149S; Y152H; S159A; V160A; L163V; 
L169K; G171A; T172R; G173A; G173Q; L174R; S177Q; 
A181K; S179R; R182K; F189A; F189K; F189L; V190K; 
Q191K; A193D; A194K; A194R; N197K; I218L; W220A; 
V225I; T254R; V262L; S265A; W285T; A310D; C477T; 65 
L508G; K531A; Y532F; D533S; Tl 72R/G 173Q; Tl 72R/ 
Al 93D; Tl 72R/F 189K; Tl 72R/G 173Q-Il 7 5-G-G-Al 86; 
9. The composition of claim 1, further comprising: 
a polymeric molecule, 
wherein the polymeric molecule is chemically linked to 
one or more ammo acid residues the mutant CocE 
polypeptide. 
US 10,160,960 B2 
27 
10. The composition of claim 9, wherein 
at least one of C107, C429, C551, and C477 is not 
substituted; and 
the polymeric molecule is chemically linked to the mutant 
CocE polypeptide at the non-substituted amino acid 5 
position selected from C107, C429, C551, and C477. 
11. The composition of claim 9, wherein the polymeric 
molecule is chemically linked to a substituted or added 
amino acid residue of the mutant CocE polypeptide. 
12. The composition of claim 9, wherein the polymeric 10 
molecule comprises a molecular weight of about 300 Dal-
tons up to about 20,000 Daltons. 
28 
Bis [2-(N-Succinimidy 1-succiny !amino )ethy !]polyethylene 
glycol; 0-(3-Carboxypropyl)-0'-[2-(3-mercaptopropio-
nylamino )ethyl]-polyethylene glycol; O-[N-(3-Maleimi-
dopropionyl )aminoethyl ]-0'-[3-(N-succinimidyloxy )-3-
oxopropyl ]triethy lene glycol; Methoxypolyethylene glycol 
azide PEG; Methoxypolyethylene glycol; and 0-[2-(3-Tri-
tylthiopropionylamino )ethyl]polyethylene glycol. 
16. The composition of claim 1, wherein the mutant CocE 
polypeptide has at least about 60%, at least about 65%, at 
least about 70%, at least about 75%, at least about 80%, at 
least about 85%, at least about 90%, at least about 95%, at 
least about 100%, at least about 105%, at least about 110%, 
at least about 115%, at least about 120%, at least about 
125%, at least about 130%, at least about 135%, or at least 
about 140% of the esterase activity of a wild-type CocE 
polypeptide. 
17. The composition of claim 1, wherein the mutant CocE 
polypeptide is at least about 2.1 kcal/mo!, at least about 2.2 
kcal/mo!, at least about 2.3 kcal/mo!, at least about 2.4 
kcal/mo!, at least about 2.5 kcal/mo!, at least about 2.6 
kcal/mo!, at least about 2.7 kcal/mo!, at least about 2.8 
kcal/mo!, at least about 2.9 kcal/mo!, at least about 3.0 
kcal/mo!, at least about 3.1 kcal/mo!, at least about 3.2 
kcal/mo!, at least about 3.3 kcal/mo!, at least about 3.4 
kcal/mo!, at least about 3.5 kcal/mo!, at least about 3.6 
kcal/mo!, at least about 3.7 kcal/mo!, at least about 3.8 
kcal/mo!, at least about 3.9 kcal/mo!, at least about 4.0 
kcal/mo!, at least about 4.1 kcal/mo!, at least about 4.2 
13. The composition of claim 9, wherein the polymeric 
molecule comprises a molecular weight of about 300 Dal-
tons, about 500 Daltons, about 750 Daltons, about 1000 15 
Daltons, about 1500 Daltons, about 2000 Daltons, about 
2500 Daltons, about 3000 Daltons, about 3500 Daltons, 
about 4000 Daltons, about 4500 Daltons, about 5000 Dal-
tons, about 5500 Daltons, about 6000 Daltons, about 6500 
Daltons, about 7000 Daltons, about 7500 Daltons, about 20 
8000 Daltons, about 8500 Daltons, about 9000 Daltons, 
about 9500 Daltons, about 10000 Daltons, about 10500 
Daltons, about 11000 Daltons, about 11500 Daltons, about 
12000 Daltons, about 12500 Daltons, about 13000 Daltons, 
about 13500 Daltons, about 14000 Daltons, about 14500 25 
Daltons, about 15000 Daltons, about 15500 Daltons, about 
16000 Daltons, about 16500 Daltons, about 17000 Daltons, 
about 17500 Daltons, about 18000 Daltons, about 18500 
Daltons, about 19000 Daltons, about 19500 Daltons, or 
about 20000 Daltons. 30 kcal/mo!, at least about 4.3 kcal/mo!, at least about 4.4 
kcal/mo!, or at least about 4.5 kcal/mo! more thermostable as 
compared to wild-type CocE. 
14. The composition of claim 9, wherein the polymeric 
molecule comprises a polyethylene glycol (PEG). 
15. The composition of claim 9, wherein the polymeric 
mo!ecule is selected from the group consisting of2-[2-(Boc-
ammo )ethoxy ]ethoxyacetic acid ( dicyclohexylammonium); 35 
21-(Boc-amino )-4, 7, 10, 13, 16, 19-hexaoxaheneicosanoic 
acid purum; 15-(Boc-amino )-4, 7, 10, 13-tetraoxapentade-
canoic acid purum; N-Boc-2,2'-(ethylenedioxy)diethylam-
me; N-Boc-N'-succinyl-4, 7, 1 O-trioxa-1, 13-tridecanedi-
amine; 2-[2-(Fmoc-amino)ethoxy]ethanol; N-Fmoc-N"- 40 
succinyl-4,7,10-trioxa-l,13-tridecanediamine· 4 7 10 13 16 
19,22,25,32,35,38,41,44,47,50,53-Hexadecao~a:28,29- ' ' 
dithiahexapentacontanedioic acid· 4 7 10 13 16 19 22 25 
32,35,38,41,44,47,50,53-Hexadeca~xa:28,29- ' ' ' ' ' 
dithiahexapentacontanedioic acid di-N-succinimidyl ester; 45 
0,0'-Bis(~-aminoethyl)octadecaethylene glycol; { 2-[2-
(Fmoc-ammo )ethoxy ]ethoxy }acetic acid; 2-[2-(2-Methoxy-
etho~y)~thoxy]acetic_ acid; methoxypolyethylene glycol 
male1m1de; 0-(2-Az1doethyl)-O'-methyl-triethylene glycol; 
0-~2-Azidoethyl)-0'-methyl-undecaethylene glycol; 0-(2- 50 
~z~do_ethyl)no~adecaethylene glycol; 0,0'-Bis[2-(N-Suc-
c1mm1dyl-succmylamino )ethyl]polyethylene glycol; 0,0'-
18. The composition of claim 1, having reduced immu-
nogenicity as compared to a composition comprising a 
wild-type CocE. 
19. The composition of claim 1, wherein the mutant CocE 
polypeptide retains at least substantially the same or greater 
catalytic efficiency of wild-type CocE polypeptide. 
20. A pharmaceutical composition comprising the com-
position of claim 1 and a pharmaceutically acceptable carrier 
or excipient. 
21. An isolated nucleic acid encoding the mutant CocE 
polypeptide of the composition of claim 1. 
22. A method of treating a cocaine-induced condition 
comprising administering to a subject in need thereof an 
effective amount of the composition of claim 1 or a com-
position comprising the isolated nucleic acid of claim 21. 
23. The method of claim 22, wherein the cocaine-induced 
condition is selected from the group consisting of cocaine 
overdose, cocaine toxicity, cocaine addiction, and cocaine 
dependence. 
* * * * * 
